Global cell and gene therapy raw material testing market

The global cell and gene therapy testing raw materials market is estimated to reach over USD 59.04 billion by 2030, growing at a CAGR of 19.18% during the forecast period.

Request for sample pages:

The market was mainly driven by an exponential increase in the clinical pipeline and the number of regulatory approvals for innovative drugs. Market players are focusing their efforts on increasing their market presence in light of the exciting growth opportunities in the contract development of cellular and genetically modified drugs.

In addition, to accelerate the R&D of their candidate programs, bio-industrialists are forging strategic collaborations with subcontractors. The increased demand for CMO/CDMO services has led to the entry of several new competitors and increased product development capabilities, both of which have a favorable effect on the market revenue. In order to improve the production of cell and gene therapies, several innovative techniques are introduced. For example, manufacturers are exploring the potential of single-use technology in manufacturing workflows. This method is increasingly popular in this field because it can speed up development while reducing production costs and lead times. In the coming years, the growth of the market is expected to be supported by these technical products in space.

List of Key Cell and Gene Therapy Raw Material Testing Market Players:
Thermo Fisher Scientific
Merck KGaA
Catalent Inc.,
Charles River
Pace Analytics Life Sciences
PLC of the Intertek group
Element Material Technology
Eurofins Scientific
Curious about this latest version of the report? Get report details @–gene-therapy-raw-material-testing-market/1327

Market dynamics:
The high frequency of cancers and other target diseases, the accessibility of reimbursements and the growing funding for gene therapy research are contributing to the expansion of the market. The biopharmaceutical sector has seen huge changes as a result of the commercialization of highly sophisticated treatments, which have also changed the number of serious and rare diseases treated. Growing increase in advanced treatment context is one of the factors fueling the expansion of cell and gene therapy manufacturing market. For cellular products and genetically modified drugs, the health sector has observed an ideal ratio between clinical success and the number of clinical studies in recent years. This is due to advances in clinical and technical understanding of the safety risks associated with the use of these products.

The development of the global cell and gene therapy raw material testing market may be limited in the coming years due to the high cost of bioassay services. Despite product development and technological advancements over the past decade, the market has been hampered by a shortage of skilled workers capable of operating sophisticated devices like flow cytometers and multimode readers. Modern and highly complicated flow cytometers and spectrophotometers produce a variety of data outputs that require specialized interpretation and analysis. So there is a global shortage of skilled workers.

Regional trends:
During the forecast period, the North American region is expected to account for the largest share of the global cell and gene therapy raw material evaluation market. The North American zone will dominate the global market for the evaluation of raw materials for cell and gene therapies owing to a growth in healthcare-related research. A few factors influencing the market in the United States include improving living standards and new innovations in the medical field. The United States is a center of complicated medical treatments for many people around the world, as it is one of the most developed countries in the world. For example, a large number of allogeneic transplant recipients are housed in a research center in the United States. With improved facilities and a wide range of treatments, the market for cell and gene therapy raw materials testing in the United States has been vital.

• In November 2021, WuXi Advanced Therapies (USA) opened a 140,000 square foot cell and gene therapy testing center. By tripling the company’s pre-testing capacity, this facility will further strengthen the Contract Testing, Development and Manufacturing Organization (CTDMO) business model and meet the growing demands of customers in the cell therapy and cell therapy industries. gene.

• In April 2021, PPD, Inc., a multinational Contract Research Organization (CRO), is expanding its GMP laboratory in Athlone, Ireland, increasing the size of its current facilities and expanding the operation’s range of services to include cell and gene therapy trial. With this growth, PPD will be better able to meet the growing demand from customers in Europe, the Middle East and Africa, and the Asia-Pacific region for global scientific and technical knowledge.

Cell and Gene Therapy Raw Material Testing Market Segmentation –
By service
• Sterility test
• Mycoplasma detection tests
• Detection of endotoxins
• Bioburden test
• Others

By type
• Cell therapy
• Genetical therapy

By region-
North America-
• United States
• Canada
• Mexico

• Germany
• Great Britain
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia-Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East and Africa-
• GCC countries
• South Africa
• Rest of the Middle East and Africa

For more information @–gene-therapy-raw-material-testing-market/1327

InsightAce Analytics Pvt. ltd.
Such. : +1 551 226 6109
Email: [email protected]
Site visit:
Follow us on LinkedIn @
Follow us on Facebook @

InsightAce Analytic is a market research and consulting company that empowers clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market intelligence and competition to grow businesses. We help our clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in delivering syndicated and customized market intelligence reports with in-depth analysis with key market insights in a timely and cost effective manner.

This press release was published on openPR.

Comments are closed.